Provide preliminary validation of the use of genetically engineered Salmonella strains, which specifically target solid tumors following systemic administration for use in non-invasive imaging and prodrug activation. The intent of long term research is to develop the properties of these Salmonella strains to create a targeting vector that will be a platform for the detection and subsequent treatment of tumors. The current project will perform studies to explore the signature Salmonella targets resulting in Salmonella localization in tumors. The project will also evaluate the ability of Salmonella to target to small tumor foci, metastases, and recurring tumors, as well as evaluate the targeting of Salmonella to tumors in additional murine models.

Agency
National Institute of Health (NIH)
Institute
Office of The Director, NCI (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CO007102-000
Application #
6336174
Study Section
Project Start
2000-08-01
Project End
Budget Start
2000-08-01
Budget End
2001-01-31
Support Year
Fiscal Year
2000
Total Cost
$141,332
Indirect Cost
Name
Vion Pharmaceuticals, Inc.
Department
Type
DUNS #
City
New Haven
State
CT
Country
United States
Zip Code
06511
Soghomonyan, Surren A; Doubrovin, Michael; Pike, Jeremy et al. (2005) Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. Cancer Gene Ther 12:101-8